International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring

Therapeutic Drug Monitoring

Volumn 24, Issue 1, 2002, Pages 59-67

  Holt, David W ^a   Armstrong, Victor W ^a   Griesmacher, Andrea ^a   Morris, Raymond G ^a   Napoli, Kimberly L ^a   Shaw, Leslie M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cyclosporine; Mycophenolic acid; Sirolimus; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ANALYTIC METHOD; AREA UNDER THE CURVE; CLINICAL CHEMISTRY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEASUREMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

ANIMALS; CYCLOSPORINE; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS; TACROLIMUS;

EID: 0036146789     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200202000-00011     Document Type: Conference Paper

References (82)

1. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine
2. Canadian Consensus Meeting on cyclosporine monitoring: Report of the consensus panel
3. Cyclosporin A monitoring in Australia: Consensus recommendations
4. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists task force
5. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
6. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus
7. Consensus document: Therapeutic monitoring of tacrolimus (FK-506)
8. Mycophenolate mofetil: A report of the consensus panel
9. Therapeutic monitoring of mycophenolic acid. A consensus panel report
10. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
11. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion
12. Consensus guidelines for therapeutic drug monitoring of rapamycin: Report of the consensus panel
13. Newer immunosuppressive drugs: A review
14. From beach to bedside: A history of the development of sirolimus
15. Monitoring new immunosuppressive agents. Are the methods adequate?
16. Reference methods as a basis for accurate measuring systems
17. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring
18. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
19. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
20. Cyclosporin measurementwho cares about inaccuracy?
21. Cyclosporin microemulsion. A guide to usage and monitoring
22. Sandimmun Neoral pharmacokinetics: Impact of the new oral formulation
23. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms
24. C(2) monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation
25. The temporal profile of calcineurin inhibition by cyclosporine in vivo
26. New approaches to cyclosporine monitoring raise further concerns about analytical techniques
27. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay
28. The international mycophenolic acid proficiency testing scheme
29. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite
30. Clinical pharmacokinetcs of mycophenolate mofetil
31. Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma
32. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
33. Quantification of mycophenolic acid in plasma samples collected during and immediately after intravenous administration of mycophenolate mofetil
34. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
35. The effect of renal insufficiency on mycophenolic acid protein binding
36. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid
37. Ultrasensitive measurement of free mycophenolic acid using HPLC with mass spectrometry detection
38. Validation of free MPA determination by ultrafiltration followed by a modified EMIT method in renal transplantation
39. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
40. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation
41. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
42. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
43. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
44. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
45. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
46. Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients
47. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid
48. MMF may be given at lower doses when used in association with sirolimus in renal transplant recipients
49. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: A link to side effects?
50. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
51. Mycophenolic acid concentrations are associated with cardiac allograft rejection
52. A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection
53. An immunoassay for the measurement of sirolimus
54. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection
55. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry
56. Proficiency-testing issues relating to sirolimus
57. Stability of sirolimus (rapamycin) in whole blood
58. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
59. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
60. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
61. Median effect analysis of efficacy versus adverse effects of immunosuppressants
62. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
63. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
64. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent
65. Sirolimus-tacrolimus combination immunosuppression
66. EMIT 2000 tacrolimus assay: A critical evaluation
67. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
68. Pitfalls in monitoring tacrolimus (FK 506)
69. Pharmacological surrogates of allograft outcome
70. Failure of traditional trough levels to predict tacrolimus concentrations
71. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients
72. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients
73. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation
74. Comparison of tacrolimus concentrations measured by the IMx tacrolimus II vs the PROTRAC II FK506 ELISA assays
75. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients
76. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
77. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
78. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation
79. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
80. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
81. Combined FTY720/cyclosporine treatment promotes graft survival and lowers the peripheral lymphocyte count in a murine cardiac allotransplantation model
82. Concentration-controlled trials: What does the future hold?